SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-019588
Filing Date
2016-05-16
Accepted
2016-05-16 17:25:50
Documents
61
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q navb-10q_20160331.htm 10-Q 1309133
2 EX-31.1 navb-ex311_7.htm EX-31.1 10585
3 EX-32.1 navb-ex321_8.htm EX-32.1 5832
  Complete submission text file 0001564590-16-019588.txt   5262940

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20160331.xml EX-101.INS 1144365
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20160331.xsd EX-101.SCH 38733
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20160331_cal.xml EX-101.CAL 44355
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20160331_def.xml EX-101.DEF 129182
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20160331_lab.xml EX-101.LAB 326626
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20160331_pre.xml EX-101.PRE 259413
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 161655297
SIC: 2835 In Vitro & In Vivo Diagnostic Substances